Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Sarepta Therapeutics
Sarepta Therapeutics
Few safe havens surface in another down quarter for biopharma
EP Vantage
Fri, 10/14/22 - 10:03 am
biopharma stocks
COVID-19
Eli Lilly
Bristol Myers Squibb
Merck
Daiichi Sankyo
Vertex Pharmaceuticals
Takeda
Neurocrine
Sarepta Therapeutics
Orion
Pfizer
GSK
Roche
Moderna Therapeutics
BeiGene
BioNTech
Novavax
CureVac
The gloom deepens for biopharma stocks
EP Vantage
Mon, 10/10/22 - 06:54 pm
biopharma stocks
AbbVie
Alnylam
AstraZeneca
Biogen
CRISPR Therapeutics
Daiichi Sankyo
Eisai
Eli Lilly
GSK
Intellia Therapeutics
Regeneron
Roche
Sanofi
Sarepta Therapeutics
Sarepta asks FDA to approve first gene therapy for Duchenne muscular dystrophy
BioPharma Dive
Thu, 09/29/22 - 07:38 pm
Sarepta Therapeutics
Duchenne Muscular Dystrophy
FDA
gene therapy
SRP-9001
Pepgen aims to overtake Sarepta
EP Vantage
Wed, 09/28/22 - 11:00 am
Sarepta Therapeutics
PepGen
Duchenne Muscular Dystrophy
PGN-ED051
Eyeing accelerated approval for Duchenne gene therapy, Sarepta hopes to bring in $1B in bid for profitability
Endpoints
Tue, 09/13/22 - 10:35 am
Sarepta Therapeutics
Duchenne Muscular Dystrophy
gene therapy
FDA
After serious side effect, Sarepta and FDA realign on next-gen Duchenne drug with trial hold lifted
Endpoints
Tue, 09/6/22 - 10:48 am
Sarepta Therapeutics
Duchenne Muscular Dystrophy
vesleteplirsen
clinical trials
Did Sarepta Therapeutics Just Unveil a Breakthrough?
TheStreet.com
Wed, 08/17/22 - 11:37 pm
Sarepta Therapeutics
Duchenne Muscular Dystrophy
FDA
Sarepta to Expedite Timeline for Muscular Dystrophy Gene Therapy
BioSpace
Thu, 08/4/22 - 10:59 am
Sarepta Therapeutics
SRP-9001
Duchenne Muscular Dystrophy
Sarepta shares buoyed by pledge to seek an early swift review for Duchenne gene therapy
Fierce Biotech
Fri, 07/29/22 - 10:20 am
Sarepta Therapeutics
SRP-9001
Duchenne Muscular Dystrophy
Roche
accelerated approvals
Myocarditis case mars Sarepta DMD gene therapy readout
Pharmaforum
Thu, 07/7/22 - 10:23 am
Sarepta Therapeutics
gene therapy
Duchenne Muscular Dystrophy
SRP-9001
myocarditis
FDA suspends US testing of Sarepta Duchenne drug over safety concerns
BioPharma Dive
Thu, 06/23/22 - 08:04 pm
FDA
Sarepta Therapeutics
Duchenne Muscular Dystrophy
SRP-5051
Pfizer, Sarepta team with fellow DMD gene therapy makers to get to the bottom of adverse events
Fierce Biotech
Tue, 05/17/22 - 10:31 pm
Duchenne Muscular Dystrophy
gene therapy
Pfizer
Sarepta Therapeutics
Genethon
Solid Biosciences
Opportunities arise for once-spurned partners
EP Vantage
Fri, 05/13/22 - 10:34 am
Pfizer
Biohaven
licensing
M&A
Aurinia
Bristol Myers Squibb
AbbVie
Alector
Arcus Biosciences
Biogen
Blueprint Medicines
CureVac
Gilead Sciences
GSK
Incyte
MorphoSys
Roche
Nestle
SAGE Therapeutics
Sarepta Therapeutics
Seres Therapeutics
Syndax
With Sarepta in its sights, PepGen prices IPO to fund DMD trials
Fierce Biotech
Fri, 05/6/22 - 10:55 am
PepGen
IPOs
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Editas brings on Sarepta CMO—for CEO swap, not the vacant CMO role
Fierce Biotech
Fri, 04/15/22 - 01:49 pm
Editas
Sarepta Therapeutics
Pharma CEOs
Gilmore O'Neill
Sarepta reveals gene editing alliance with biotech exploring alternative delivery methods
BioPharma Dive
Tue, 02/1/22 - 11:18 pm
Sarepta Therapeutics
gene editing
gene therapy
GenEdit
Sarepta says early filing for DMD gene therapy may be back on
Pharmaforum
Wed, 01/12/22 - 10:53 am
Sarepta Therapeutics
Duchenne Muscular Dystrophy
SRP-9001
Sarepta DMD Treatment Improves Motor Skills in Study Presented at JPM
BioSpace
Tue, 01/11/22 - 11:41 am
Sarepta Therapeutics
delandistrogene moxeparvovec
Duchenne Muscular Dystrophy
JPMHC 2022
Sarepta, with new Duchenne results, to broach 'possibility' of speedy gene therapy approval
BioPharma Dive
Mon, 01/10/22 - 11:39 pm
Sarepta Therapeutics
Duchenne Muscular Dystrophy
gene therapy
Moderna, Amgen among biotech heavyweights pulling out of JPM conference over Covid concerns
Stat
Tue, 12/14/21 - 11:37 pm
JPMHC 2022
Amgen
Moderna
Sarepta Therapeutics
COVID-19
pandemic
Omicron COVID-19 variant
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »